Management of acute severe ulcerative colitis—an update for generalist and specialist clinicians
British Medical Bulletin · 2024
DOI: 10.1093/bmb/ldae006 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift British Medical Bulletin, 2024. Verfasst von Anish J Kuriakose Kuzhiyanjal und 1 weiteren Autor:innen. Beteiligte Einrichtung: Digestive Diseases Unit, Aintree University Hospital, Lower Ln, Fazakerley, Liverpool L97AL, UK. Hauptthemen laut MEDLINE: Colitis, Ulcerative. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background Acute severe ulcerative colitis (ASUC) is a potentially life-threatening medical emergency that occurs in up to 25% of patients with ulcerative colitis. Although intravenous corticosteroids remain the cornerstone of therapy, 30–40% of patients will not respond and need timely consideration of rescue therapy with (currently) either infliximab or ciclosporin or indeed colectomy, underscoring the importance of multidisciplinary care to ensure favourable outcomes for patients. We discuss the current evidence and present an approach to the management of ASUC for general and specialist clinicians caring for patients with ASUC. Sources of data The information in this review is derived from data published in peer- reviewed academic journals and registered clinical trials. Areas of agreement Management of acute severe colitis requires a multidisciplinary approach with early initiation with steroids and timely escalation of treatment to either medical rescue therapy or surgery. Areas of controversy Balancing the risks of delayed surgery vs. optimizing medical therapy, including accelerated dosing schedules for biologics, remains ambiguous. Growing points The position on newer molecules like Janus Kinase inhibitors, such as tofacitinib, is a growing area with early real-world data showing promise for steroid refractory ASUC. Areas timely for developing research Developing predictive biomarkers and clinical risk scores for personalized rescue therapy selection is an evolving area of research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Digestive Diseases Unit, Aintree University Hospital, Lower Ln, Fazakerley, Liverpool L97AL, UK.
- Division of Gastroenterology-Section of IBD, Northern Care Alliance NHS Foundation Trust, Rochdale Old Rd, Bury, Manchester BL97TD, UK.
- Manchester Academic Health Sciences, University of Manchester, Oxford Rd, Manchester M139PL, UK.
ORCID-Profile: Anish J Kuriakose Kuzhiyanjal, Jimmy K Limdi
Zitieren
APA
Kuriakose Kuzhiyanjal, A. J., & Limdi, J. K. (2024). Management of acute severe ulcerative colitis—an update for generalist and specialist clinicians. British Medical Bulletin. https://doi.org/10.1093/bmb/ldae006
Vancouver
Kuriakose Kuzhiyanjal AJ, Limdi JK. Management of acute severe ulcerative colitis—an update for generalist and specialist clinicians. British Medical Bulletin. 2024. doi:10.1093/bmb/ldae006
BibTeX
@article{KuriakoseKuzhiyanjal2024,
author = {Kuriakose Kuzhiyanjal, Anish J and Limdi, Jimmy K},
title = {Management of acute severe ulcerative colitis—an update for generalist and specialist clinicians},
journal = {British Medical Bulletin},
year = {2024},
doi = {10.1093/bmb/ldae006}
}
EUVIMED